Citigroup’s Amylyx Pharmaceuticals AMLX Stock Holding History

Citigroup’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-71,700	Closed	-$1.06M	–	5624
2023 Q4	$1.06M	Buy	71,700 +13,500	+23%	+$207K	﹤0.01%	2779
2023 Q3	$1.07M	Sell	58,200 -2,500	-4%	-$52.9K	﹤0.01%	2453
2023 Q2	$1.31M	Buy	60,700 +55,700	+1,114%	+$1.5M	﹤0.01%	2616
2023 Q1	$147K	Sell	5,000 -48,100	-91%	-$1.67M	﹤0.01%	3885
2022 Q4	$1.96M	Sell	53,100 -20,600	-28%	-$731K	﹤0.01%	2051
2022 Q3	$2.08M	Buy	+73,700	New	+$1.84M	﹤0.01%	2114

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Citigroup's AMLX Position: Q3 2026 in Review

Citigroup reduced its Amylyx Pharmaceuticals (AMLX) stake by 48% in Q3 2026, selling an estimated $870K and leaving 35,852 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3285.

Citigroup first reported a position in AMLX in Q1 2022 and has held it in 19 quarters since. The position peaked at $5.71M in Q4 2023. 111 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

Citigroup held 35,852 shares of Amylyx Pharmaceuticals worth $1.04M as of Q3 2026.
Citigroup sold 32,832 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $870K.
Amylyx Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3285 holding.
Citigroup first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 19 quarters since.
Citigroup's Amylyx Pharmaceuticals position peaked at $5.71M in Q4 2023.
111 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.